Figure 4.

ICL1-9 protects against cardiomyocyte death in vitro. ¹²⁵I-cyanopindolol binding analysis of NRVM treated for 1 h (A) or 24 h (B) with Veh, ISO, Scr or ICL1-9 pepducin (10 μM each). n=4 Veh, n=4 ISO, n=5 Scr, n=5 ICL1-9. *p < 0.05, *** p < 0.001 for β1AR density, one-way ANOVA with Tukey's multiple comparison test. (C) Caspase 3/7 activity was measured in NRVM subjected to 24 h with or without serum in the presence of Scr or ICL1-9 pepducin (10 µM each) with values represented as a percentage of no serum Veh control. n=7 Veh, n=7 Veh no serum, n=10 Scr no serum, n=10 ICL1-9 no serum. ns = not significant, ** p < 0.01, *** p < 0.001, one-way ANOVA with Tukey's multiple comparison test. (D) Caspase 3/7 activity was measured in NRVM subjected to 24 h without serum in the presence of Scr or ICL1-9 pepducin (10 µM each) and pretreated with PD98059, LY294002 or AG1478 (10 µM each) with values represented as a percentage of Veh Scr. n=18 Veh Scr, n=20 Veh ICL1-9, n=10 PD98059 Scr and PD98059 ICL1-9, n=8 for all other treatment groups. ns = not significant, ** p < 0.01, *** p < 0.001, one-way ANOVA with Tukey's multiple comparison test.